Aims-To assess the quality ofcentres contributing antimicrobial susceptibility data to a centralised database. Methods-Twelve organisms were distributed to 31 regional microbiology laboratories contributing data to a centralised susceptibility database. Participants were asked to determine susceptibilities to certain antibiotics by their routine method and return the data to the Department of Microbiology, Royal Hallamshire Hospital, Sheffield, for analysis. Results-Results for the overwhelming majority of organism/antibiotic combinations were in agreement with expected results. Reasons for discrepancies included the non-bimodal distribution of susceptibilities, the use ofdifferent content discs, and, more importantly, minimum inhibitory concentrations falling close to breakpoint values. Conclusions-It is inevitable that any large multicentre database will contain a degree of inaccurate data. This study has highlighted several areas where discrepant results have occurred and has enabled Glaxo Laboratories to approach individual laboratories to address this problem. This study emphasises the value and consistency of Microbe Base as the largest database, of its kind, nationally.
Epidemiological surveillance is an important function of microbiology laboratories. Microbe Base is a computer software suite,'2 developed in Sheffield, that allows microbiology laboratories to store and analyse antimicrobial susceptibility data using personal computers. At the Department of Microbiology, Royal Hallamshire Hospital, Sheffield, we have used these programs to perform computed surveillance for the past 14 years. We also recognised the programs' potential for collecting multicentre susceptibility data. Glaxo Laboratories distributed the program suite to 61 centres throughout the UK, producing the largest incidence and susceptibility survey to date. 3 They have now developed a number of individual formats so that anonymous patient data can be down-loaded from hospital computer systems onto floppy disks for transfer to the mainframe computer at Glaxo which houses the Microbe Base national database and currently holds in excess of one million records.
Prior to this study, there had been no attempt to assess the quality of data stored in Microbe Base, other than individual laboratories' voluntary participation in external quality assurance schemes such as the National External Quality Assurance Scheme (NEQAS). 6 The aim ofthis study was to determine the suitability of centres contributing data towards the Microbe Base national database.
Methods
Twelve organisms were distributed to 31 laboratories routinely using Microbe Base for storage of antimicrobial susceptibility data. The organisms comprised three well characterised control strains: Staphylococcus aureus NCTC 6571, Escherichia coliNCTC 10418 and Pseudomonas aeruginosa NCTC 10662. These were said to be isolated from blood, urine and a wound, respectively. Eight clinical strains were said to be isolated from a variety of sites (E coli from blood; S aureus from a wound; P aeruginosa from blood; Haemophilus influenzae from blood and cerebrospinal fluid; Kiebsiella oxytoca from a wound; Enterobacter cloacae from urine; and Streptococcus pneumoniae from cerebrospinal fluid). These were identified using standard laboratory procedures.78 Minimum inhibitory concentrations (MICs) were determined using diagnostic sensitivity test (DST) agar (Unipath) supplemented, when necessary, with lysed horse blood (2%) and nicotinamide adenine dinucleotide (NAD, 20 mg/1), an inoculum of 105 organisms per spot, and incubation at 37°C for 18 hours. Methicillin MICs were determined at 30°C. Susceptibility was assigned by reference to the Working Party of the British Society for Antimicrobial Chemotherapy.9 The three control organisms were chosen because most centres used these as controls for disc diffusion tests. The others were included to be representative of antibiotic resistance patterns found in common pathogens. The twelfth strain (organism 10) was found to be a mixed culture and was not included in the analysis. Participants were asked to determine susceptibilities to certain antibiotics only; these data were returned to the Department of Microbiology at the Royal Hallamshire Hospital for analysis.
Results
Of the 31 participating centres, 29 used disc diffusion as a routine susceptibility method; seven also used agar dilution and one also used [1] [2] [3] [4] [5] [6] . Organisms 1 and 6 were strains of S aureus said to be isolated from blood and wound sites, respectively. In reality, organism 1 was NCTC 6571 (the Oxford staphylococcus) and organism 6 was a methicillin resistant staphylococcus (EMRSA- 1 5) . Results from all centres were in accordance with expected results for both organisms tested against gentamicin, penicillin, erythromycin, and methicillin. However, one centre reported false resistance of strain 1 to cefuroxime. This was surprising as this centre used the comparative technique with 30 tg discs and NCTC 6571 as control; it was, however, the only laboratory not to use a suspending fluid for the inoculum. One centre reported strain 6 as susceptible to cefuroxime (but resistant to methicillin): this centre used methodology similar to that used by others (Stokes' technique with 30 jig discs).
Organism 2 was a strain of E coli said to be isolated from urine. In reality, this was NCTC 10418 and all centres found the organism to be susceptible to trimethoprim, ampicillin, cephalexin, ciprofloxacin, gentamicin, cefuroxime, ceftazidime, imipenem, and amoxycillin/clavulanate. All centres found organism 8 (E cloacae from urine) to be susceptible to ciprofloxacin, ceftazidime and imipenem. Three centres, using typical disc strengths of 1 Had the strains in this study been from clinical samples, some results may have profoundly affected patient management. For example, strain 12 was a chloramphenicol resistant strain of H influenzae, said to be isolated from cerebrospinal fluid. Three centres reported this organism as spuriously susceptible.
It is inevitable that a large multicentre database such as Microbe Base will contain a degree ofinaccurate data. Omitting strain 7 (as already discussed), we estimate the error in this study to be 6% of organism/antibiotic combinations. This is not to say that the error in Microbe Base data is also 6%. Participating centres knew that these organisms were control strains, and their analysis represented a relatively narrow range of organism/antibiotic combinations.
This exercise has enabled Glaxo Laboratories to approach individual laboratories to address this problem, and emphasises the value and consistency ofMicrobe Base as the largest database, of its kind, nationally.
